biotech
Will the FDA approve UX111 (ABEO) on/around 2026-09-19? Sanfilippo syndrome A
EHIQ
75%
Market
—
Divergence
—
The why is Premium
The full stated basis, the stamped fact-check, what the market may be mispricing, what changed since the call opened, and what would strengthen or break the thesis — that depth is the Premium tier ($249/month).
This week's public showcase: prez 2028 ossoff →
The numbers above are always free — comprehension is never gated. The divergence is a difference of opinion, not a trade recommendation.